Core Viewpoint - Clearmind Medicine Inc. has achieved a significant milestone by dosing the first participant with its proprietary drug candidate CMND-100 in a Phase I/IIa clinical trial aimed at treating Alcohol Use Disorder (AUD) [1][3]. Group 1: Clinical Trial Details - The Phase I/IIa trial is being conducted at prestigious clinical sites, including Yale School of Medicine, Johns Hopkins University, and medical centers in Israel [2]. - The trial's objectives include evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, as well as assessing its preliminary efficacy in reducing alcohol cravings and consumption [2][3]. - This trial represents the first time Clearmind's neuroplastogen compound has been administered to humans in a controlled clinical setting [3]. Group 2: Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, particularly AUD [4]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5].

Core Insights - Clearmind Medicine Inc. has added Hadassah-University Medical Center in Jerusalem as a new clinical site for its Phase I/IIa trial of CMND-100, a drug candidate for Alcohol Use Disorder (AUD) [1][2] - The trial aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100, while also assessing its potential to reduce alcohol cravings and consumption [3] - Alcohol Use Disorder affects over 280 million people globally, indicating a significant unmet medical need and a potential multibillion-dollar market opportunity [4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [7] Clinical Trial Details - The inclusion of Hadassah-University Medical Center is expected to enhance patient recruitment, accelerate data collection, and increase the statistical power of the study [3][5] - Other participating institutions include Yale School of Medicine, Johns Hopkins University, and Tel Aviv Sourasky Medical Center [2]

Core Insights - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD), which affects hundreds of millions globally [1][2] - The trial's primary focus is on evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy assessments to determine its potential in reducing alcohol cravings and consumption [2] Company Overview - Clearmind is a clinical-stage biotech company dedicated to developing novel psychedelic-derived therapeutics to address significant health issues, including AUD [4] - The company has a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] Market Potential - The substance use disorder treatment market in the U.S. was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029, indicating a significant opportunity for innovative treatments like CMND-100 [3]

Core Insights - Clearmind Medicine Inc. is advancing its mission to develop psychedelic-derived therapeutics by engaging a prominent government and political affairs consulting firm to navigate regulatory landscapes and promote acceptance among U.S. policymakers [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing novel psychedelic-derived therapeutics aimed at addressing major under-treated health issues, including alcohol use disorder [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [5] Industry Context - The pharmaceutical industry is increasingly recognizing the potential of psychedelics to treat conditions such as Post-Traumatic Stress Disorder (PTSD) and other mental health disorders, necessitating informed regulatory frameworks to facilitate the integration of these therapies into mainstream healthcare [2][3] - Clearmind's lead candidate, CMND-100, is currently undergoing Phase I/IIa clinical trials for alcohol use disorder at prestigious institutions, including Yale School of Medicine and Johns Hopkins University [3]

Core Viewpoint - Clearmind Medicine Inc. has expanded its Phase I/IIa clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder (AUD), by adding Tel Aviv Sourasky Medical Center as a clinical site, following the enrollment of the first patient [1][3]. Group 1: Clinical Trial Expansion - The addition of Tel Aviv Sourasky Medical Center, led by Dr. David Zeltser, enhances the trial's capacity to evaluate CMND-100's safety, tolerability, and pharmacokinetic profile [2]. - Other prestigious institutions involved in the trial include Yale School of Medicine and Johns Hopkins University, indicating a strong clinical network [2][3]. Group 2: Company Objectives and Focus - Clearmind is focused on developing novel psychedelic-derived therapeutics to address major under-treated health issues, particularly AUD, which affects millions and is responsible for 2.6 million deaths annually [3][4]. - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4]. Group 3: Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents to strengthen its position [5].

Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Six Months Ended April 30, 2025 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) | | April 30, | | October 31, | | --- | --- | --- | --- | | | 2025 | | 2024 | | Assets | | | | | Current assets | | | | | Cash and cash equivalents | $ 4,472,520 | | $ 6,573,813 | | Other ...

Core Insights - Clearmind Medicine Inc. has engaged a leading government and political affairs consulting firm to advance its mission of developing psychedelic-based therapeutics [1][2] - The company aims to navigate complex regulatory landscapes and promote acceptance of psychedelic therapies among U.S. policymakers [2][3] - Clearmind's lead candidate, CMND-100, is currently in Phase I/IIa clinical trials for alcohol use disorder (AUD) at prestigious institutions [3] Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing psychedelic-derived therapeutics to address under-treated health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Industry Context - The pharmaceutical industry is increasingly recognizing the potential of psychedelics to treat mental health disorders such as PTSD [2] - The partnership with the consulting firm aims to educate policymakers on the therapeutic potential of psychedelics and support the development of balanced regulations [3]

Core Insights - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel oral drug candidate aimed at treating Alcohol Use Disorder (AUD), with the first patient enrolled at Yale School of Medicine [1][2] - The trial will assess the safety, tolerability, and pharmacokinetic profile of CMND-100, along with preliminary efficacy in reducing alcohol cravings and consumption [2] - The U.S. substance use disorder treatment market was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029, highlighting significant market potential for effective AUD treatments [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [4] - The company holds a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Clinical Trial Details - Eligible participants for the trial include individuals aged 18 to 60, either heavy binge drinkers or those diagnosed with AUD, who express a desire to reduce or stop drinking [3] - The trial is being conducted at multiple sites, including Yale School of Medicine and Johns Hopkins University School of Medicine, with additional sites under evaluation [3]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in a European patent application for a combination treatment targeting cocaine addiction [1][4] - The patent application is based on preclinical trial results showing that Clearmind's MEAI significantly reduces cocaine-induced craving in animal models [2] - Further research indicates that MEAI specifically targets drug-related compulsions without impairing responses to natural rewards, suggesting a focused mechanism of action [3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals, with ongoing drug development programs for conditions such as Tourette Syndrome, Alzheimer's disease, and autism [5] - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for health issues like alcohol use disorder, holding a portfolio of 19 patent families and 31 granted patents [6]

Core Insights - Clearmind Medicine Inc. has announced the publication of a European patent application, strengthening its global intellectual property position and focusing on addiction treatment [1][2] Intellectual Property - The patent EP 4531826 covers Clearmind's proprietary psychedelic-based combination therapy, which includes MEAI and certain N-Acylethanolamines for treating cocaine addiction [2] - The company's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [7] Research and Development - Preclinical trials led by Professor Gal Yadid at Bar-Ilan University demonstrated that MEAI significantly reduced cocaine-induced cravings in animals [3] - Further studies showed that MEAI reduced cocaine-seeking behavior without impairing responses to natural rewards, indicating a targeted effect on drug-related compulsions [4] Strategic Collaboration - The patent application is part of an ongoing collaboration with SciSparc Ltd. to explore the combined potential of MEAI and PEA-based technologies for treating central nervous system disorders [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health problems, including substance use disorders [6]